ࡱ> ;=: bjbj 8$ 33333GGGGD G.4666666a63633K*3344P)qyGj a0qvqq366vq : Dopamine Beta-Hydroxylase (DBH) Activity and -1021C/T Polymorphism of DBH Gene in Alzheimers disease M. Mustapic1, P. Presecki 3, N. Mimica 2, N. Pivac1,V. Folnegovic-Smalc 2, M. Diksic4, D. Muck- Seler 1 1Division of Molecular Medicine R.Boskovic, Institute, Zagreb, 2Department of Psychiatry, Psychiatric Hospital Vrapce, Zagreb, 3General Hospital Pula, Department of Psychiatry, Pula, Croatia 4 Department of Neurology and Neurosurgery, McGill University, Montreal, Canada  HYPERLINK "mailto:seler@irb.hr" maja.mustapic@irb.hr Background: Alzheimers disease (AD) is complex and polygenic disorder. Polymorphisms within the dopamine beta-hydroxylase (DBH) gene could be related to etiology of Alzheimers disease (AD), given the well-documented changes in the catecholamine-mediated neurotransmission that occurs in this disorder. The aim of the present study was to investigate DBH -1021C/T gene polymorphism and plasma DBH activity between patients with AD and healthy controls. Methods: Plasma DBH activity and DBH -1021C/T polymorphism were determined in 155 patients (mean SD age 66.3 11.2 years; MMSE = 13.1 8.1) with AD (NINCDS-ADRDA and DSM-IV-TR criteria) and 188 healthy controls (66.3 11.2 years). The patients were subdivided into two subgroups according to the presence or absence of psychotic features and according to the early (F00.0) or late (F00.1) onset AD. Plasma DBH activity was determined by a photometric method and DBH genotype by standard RFLP technique. Results: Among AD patients 62%, 31% and 6.5% were carrying CC, CT and TT genotype, while 61.5%, 33,5% and 5.3% of healthy controls were carrying CC, CT and TT genotype, respectively. DBH genotype (Chi-square=0.38; df=2; p=0.825) and allele (Chi-square=0.038; df=1; p=0.90) frequencies were similarly distributed between healthy controls and patients with AD, between patients with or without psychotic features (Chi-square=1.90; df=2; p=0.386) and between patients with early- and late-onset AD (Chi-square=3.07; df=2; p=0.215). A significantly (p<0.001) lower plasma DBH activity was found in AD patients compared to healthy controls, there was a significant difference in plasma DBH activity (p<0,0001) between different genotypes but interaction tested between the two independent factors gave no significant difference. Conclusion: The results suggest that genotype-controlled measurement of plasma DBH activity might be used as a potential biological marker in AD.  )-.FIJefgrsuxٮueuZeuhK:OJQJ^JhKhBi:H*OJQJ^JhKhBi:OJQJ^Jh:^hBi:H*OJQJ^Jh:^hBi:OJQJ^Jh`jh.!BOJQJ^J(h.!Bh7mRCJ OJQJ^JaJ mH sH +h.!Bh.!B6CJ OJQJ^JaJ mH sH "h.!BCJ OJQJ^JaJ mH sH (h.!Bh.!BCJ OJQJ^JaJ mH sH  fg T  dhgdE$ dha$gd,y( $dha$gd,y($a$gd$gdBigd.!B 7$8$H$gd.!B  T U   м{bM1b7jhBihO:CJOJQJU^JaJmH sH (hBihO:CJOJQJ^JaJmH sH 1jhBihO:CJOJQJU^JaJmH sH +hsB*CJOJQJ^JaJmH phsH 1hBihBiB*CJOJQJ^JaJmH phsH #h:^hBiCJOJQJ]^JaJ&h:^hBiCJH*OJQJ]^JaJ h:^hBiCJOJQJ^JaJ#h:^hBiCJH*OJQJ^JaJh:^hBiOJQJ^J    + , g h P лkR='=+hBihE6CJOJQJ^JaJmH sH (hBihECJOJQJ^JaJmH sH 0hBih`jCJOJQJ^JaJmH nHsH tH(hBih`jCJOJQJ^JaJmH sH (hBih.!BCJOJQJ^JaJmH sH (hBihCJOJQJ^JaJmH sH  hBihO:OJQJ^JmH sH (hBih$CJOJQJ^JaJmH sH 1jhBihO:CJOJQJU^JaJmH sH ,hBih0JCJOJQJ^JaJmH sH  Ӿw^E/+hBih$CJOJQJ\^JaJmH sH 0hBih^} CJOJQJ^JaJmH nHsH tH0hBihiCJOJQJ^JaJmH nHsH tH0hBih$CJOJQJ^JaJmH nHsH tH0hBih7)CJOJQJ^JaJmH nHsH tH(hBih7)CJOJQJ^JaJmH sH (hBih$CJOJQJ^JaJmH sH +hBih#M6CJOJQJ^JaJmH sH +hBih$6CJOJQJ^JaJmH sH  9 B i v x > ? Y a b i j q r x տ몕oZHZH"hWhCJOJQJ^JaJmH sH (hBihCJOJQJ^JaJmH sH  hBihCJOJQJ^JaJ(hBihQCJOJQJ^JaJmH sH (hBihxSCJOJQJ^JaJmH sH (hBih2wCJOJQJ^JaJmH sH +hBih7)6CJOJQJ^JaJmH sH +hBih`j6CJOJQJ^JaJmH sH (hBih`jCJOJQJ^JaJmH sH x z { ulWlB,B+hBih;/6CJOJQJ^JaJmH sH (hBih;/CJOJQJ^JaJmH sH (hBih7)CJOJQJ^JaJmH sH (hBihxJCJOJQJ^JaJmH sH (hBih.!BCJOJQJ^JaJmH sH (hBihCJOJQJ^JaJmH sH +hBihxS6CJOJQJ^JaJmH sH (hBihxSCJOJQJ^JaJmH sH (hBih`jCJOJQJ^JaJmH sH (hBihCJOJQJ^JaJmH sH  IJRVvC֯뚅p[pE+hBih4+j6CJOJQJ^JaJmH sH (hBih.!BCJOJQJ^JaJmH sH (hBih$CJOJQJ^JaJmH sH (hBihn)CJOJQJ^JaJmH sH (hBih4+jCJOJQJ^JaJmH sH "hWhCJOJQJ^JaJmH sH (hBih)CJOJQJ^JaJmH sH (hBih;/CJOJQJ^JaJmH sH (hBih;CJOJQJ^JaJmH sH )޼޸h,0h)h7mR hBihCJOJQJ^JaJ hBihxJCJOJQJ^JaJ hBihiCJOJQJ^JaJ hBihCJOJQJ^JaJ 6&P 1h:pK. A!"#$% DyK  seler@irb.hryK (mailto:seler@irb.hr^ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ ``NormalCJ_HaJmHsHtH DA`D Default Paragraph FontRiR  Table Normal4 l4a (k (No List :B: i Body Text$dha$6U@6 ,0 Hyperlink >*B*phPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] $ x    X8@0(  B S  ?gruQTU]> ) - gST 33fg+,abqruv  fg+,abqruv  ) *Hq;:qW^} ytQX,y(,0.!B^KEL#MQ7mR``jPbJLgBi4+j`jIo[uqOtw2wz x{:jzxJKa_o$;'/li)ZBO:WhEn)Np$s;/7)xS6 @ P@UnknownG* Times New Roman5Symbol3. * Arial5. *aTahomaA BCambria Math"q3ҦrՆrՆOrArA#x24d 2qHX ?``2!xxS Dopamin-beta hidroksilaza, bioloaki i genetski pokazatelj u Alzheimerovoj bolesti Dorotea Mck-`eler Maja MustapiOh+'00<HX p|    \„Dopamin-beta hidroksilaza, biološki i genetski pokazatelj u Alzheimerovoj bolesti“Dorotea Mück-ŠelerNormal Maja Mustapić6Microsoft Office Word@B @|-Qt@@TXyrA՜.+,D՜.+,< hp|  IRB  TDopamin-beta hidroksilaza, bioloki i genetski pokazatelj u Alzheimerovoj bolesti Title 8@ _PID_HLINKSA`Vlmailto:seler@irb.hr  !"#$%&'()+,-./013456789<Root Entry FNqy>Data 1TableqWordDocument8$SummaryInformation(*DocumentSummaryInformation82CompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q